Circular <scp>RNA SPI1</scp> expression before and after induction therapy and its correlation with clinical features, treatment response, and survival of acute myeloid leukemia patients
Ting Xiong, Liqun Xia, Qiaoqiao Song
Abstract
Abstract Background Circular RNA spi‐1 proto‐oncogene (circ‐SPI1) regulates cell proliferation, apoptosis, and bone marrow differentiation in acute myeloid leukemia (AML). This study aimed to assess the relationship of circ‐SPI1 expression with the clinical features, induction therapy response, and survival of AML patients. Methods In total, 80 AML patients were included with bone marrow (BM) samples collected at baseline and after induction therapy. Additionally, 20 healthy donors (HDs) and 20 disease controls (DCs) were enrolled with BM samples collected after enrollment. BM circ‐SPI1 expression was detected by reverse‐transcription quantitative polymerase chain reaction assay. Results Circ‐SPI1 expression was highest in AML patients, moderate in DCs, and lowest in HDs (median (interquartile range): 3.01 [2.02–4.14] versus 1.71 [1.01–2.85] versus 0.98 [0.74–1.71]) ( p < 0.001). Moreover, lower circ‐SPI1 expression was related to its decreased located gene SPI1 expression ( p = 0.029), white blood cells (WBC) < 18.8 × 10 9 /L ( p = 0.010), trisomy 8 ( p = 0.025), and more favorable risk stratification ( p = 0.014) in AML patients. Additionally, circ‐SPI1 expression was reduced in AML patients after induction therapy ( p < 0.001), and its low expression after induction therapy was correlated with the achievement of complete remission ( p < 0.001). Furthermore, circ‐SPI1 decline ≥30% during therapy (versus <30%) was independently related to longer event‐free survival (EFS) (hazard ratio (HR): 0.445, p = 0.028) and overall survival (OS) (HR: 0.319, p = 0.025) in AML patients. Conclusion Decreased circ‐SPI1 expression is related to lower WBC, favorable risk stratification, and better therapy response; moreover, its decline during therapy is an independent factor to predict longer EFS and OS in AML patients.